
Molly HydeUniversity of Toronto | U of T · Institute of Medical Sciences
Molly Hyde
Doctor of Philosophy
About
16
Publications
1,344
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
32
Citations
Citations since 2017
Introduction
Additional affiliations
May 2016 - present
University of Ottawa Institute of Mental Health Research
Position
- Project Manager
April 2015 - December 2015
University of Ottawa Institute of Mental Health Research
Position
- Research Assistant
Education
January 2016 - December 2017
September 2010 - May 2015
Publications
Publications (16)
Background and objective
Repetitive transcranial magnetic stimulation (rTMS) is an effective and safe treatment for major depressive disorder (MDD). rTMS is in need of a reliable biomarker of treatment response. High frequency (HF) dorsolateral prefrontal cortex (DLPFC) rTMS has been reported to induce significant changes in the cardiac activity of...
In schizophrenia, a disorder associated with N-methyl-D-aspartate receptor (NMDAR) hypofunction, auditory cortical plasticity deficits have been indexed by the synchronized electroencephalographic (EEG) auditory steady-state gamma-band (40-Hz) response (ASSR) and the early auditory evoked gamma-band response (aeGBR), both considered to be target en...
BACKGROUND
Major depressive disorder (MDD) is now the first cause of disability worldwide. So far, no validated and scalable biomarker has been identified to help with response prediction to antidepressant treatment. Cardiac biomarkers such as heart rate variability (HRV) have been studied in MDD, but few studies have examined its potential use for...
Background
Repetitive transcranial magnetic stimulation (rTMS) is an effective intervention for major depressive disorder (MDD). Completing a full treatment course, however, is costly and time-consuming. Biomarkers of clinical outcome such as baseline resting-state brain activity measured with electroencephalography (EEG) may spare people futile tr...
Although effective in major depressive disorder (MDD), repetitive transcranial magnetic stimulation
(rTMS) is costly and complex, limiting accessibility. To address this, we tested the feasibility of novel rTMS
techniques with cost-saving opportunities, such as an open-room setting, large non-focal parabolic coils, and
custom-built coil arms. We em...
BACKGROUND
Repetitive transcranial magnetic stimulation (rTMS) is an effective intervention in major depressive disorder (MDD) but requires daily travel to a treatment clinic over several weeks. Shorter rTMS courses retaining similar effectiveness would thus increase the practicality and scalability of the technique, and therefore its accessibility...
BACKGROUND
Repetitive transcranial magnetic stimulation (rTMS) is an effective intervention in major depressive disorder (MDD) but requires daily travel to a treatment clinic over several weeks. Shorter rTMS courses retaining similar effectiveness would thus increase the practicality and scalability of the technique, and therefore its accessibility...
BACKGROUND
Repetitive transcranial magnetic stimulation (rTMS) is effective in major depressive disorder (MDD). However, technical complexity and operational costs might have been barriers for its wide use and implementation in some jurisdictions, thereby decreasing accessibility.
OBJECTIVE
Our main goal was to test the feasibility of a novel rTMS...
Objective
The effects of GABA modulating drugs and nicotine, the prototypical nicotinic cholinergic agonist, on attention have been investigated using subcomponents of the P300 event‐related potentials (ERP), which index involuntary (P3a) and voluntary attention (P3b). However, investigations into how such pharmacologic effects interact with geneti...
Projects
Project (1)
Investigation into the effects of monophasic versus biphasic rTMS on clinical and cognitive symptomatology in treatment-resistant major depressive disorder as indexed by the auditory P300 event-related potential